指南与共识其他结缔组织病类风湿关节炎

ERS/EULAR 结缔组织病相关间质性肺病临床实践指南(由欧洲呼吸学会与欧洲抗风湿病联盟结缔组织病相关间质性肺病工作组制定,获欧洲罕见呼吸疾病参考网络认可)

ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG).
指南 / 共识 · Ann Rheum Dis · 2025-09-04

欧洲呼吸学会与欧洲抗风湿病联盟工作组采用 GRADE 方法,针对系统性硬化症、类风湿关节炎、特发性炎症性肌病、干燥病、系统性红斑狼疮和混合性结缔组织病相关间质性肺病,就 25 个 PICO 问题和 28 个叙述性问题形成推荐。在混合性结缔组织病、干燥病和系统性红斑狼疮的间质性肺病筛查与进展风险评估及非类风湿关节炎相关间质性肺病的吡非尼酮问题上,证据不足未形成推荐。

要点

  • 指南覆盖系统性硬化症、类风湿关节炎、特发性炎症性肌病、干燥病、系统性红斑狼疮和混合性结缔组织病相关间质性肺病。
  • 工作组就 25 个 PICO 问题和 28 个叙述性问题给出推荐,并制定筛查、诊断、监测和治疗流程。
  • 混合性结缔组织病、干燥病和系统性红斑狼疮的间质性肺病筛查与进展风险评估证据不足,未形成推荐。

核心结论

  • 指南为每种结缔组织病相关间质性肺病提供基于证据的实用推荐,但许多情况下证据确定性低或缺乏证据,工作组鼓励进一步研究填补空白。

研究设计与样本

  • 欧洲呼吸学会与欧洲抗风湿病联盟工作组由呼吸科、风湿科、病理科、放射科、方法学家和患者代表组成。
  • 基于 PICO 问题并采用 GRADE 方法分级证据,辅以两学会商定的叙述性问题,使用 Evidence to Decision 框架形成推荐。

主要发现

  • 工作组针对 25 个 PICO 问题和 28 个叙述性问题形成推荐,涉及系统性硬化症、类风湿关节炎、特发性炎症性肌病、干燥病、系统性红斑狼疮和混合性结缔组织病相关间质性肺病。
  • 四个关于混合性结缔组织病、干燥病和系统性红斑狼疮中间质性肺病筛查与进展风险评估的叙述性问题,以及一个关于非类风湿关节炎相关间质性肺病中吡非尼酮的 PICO 问题,证据不足以支持推荐。
  • 基于推荐和常规临床实践制定了筛查、诊断、监测和治疗流程。

临床怎么用

  • 指南为临床医生针对每种结缔组织病相关间质性肺病提供基于证据的推荐作为实用指导。
  • 对于混合性结缔组织病、干燥病和系统性红斑狼疮的间质性肺病筛查与进展风险评估,以及非类风湿关节炎相关间质性肺病的吡非尼酮,原文未据此给出推荐。

局限性

  • 许多情况下证据确定性低或缺乏证据。
  • 工作组鼓励进一步研究以填补证据空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interstitial lung disease (ILD) is a frequent manifestation of connective tissue diseases (CTDs) and is associated with high morbidity and mortality. Clinical practice guidelines to standardise screening, diagnosis, treatment and follow-up for CTD-ILD are of high importance for optimised patient care. METHODS: A European Respiratory Society and European Alliance of Associations for Rheumatology task force committee, composed of pulmonologists, rheumatologists, pathologists, radiologists, methodologists and patient representatives, developed recommendations based on PICO (Patients, Intervention, Comparison, Outcomes) questions with grading of the evidence according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology and complementary narrative questions agreed on by both societies. For both PICO and narrative questions, the Evidence to Decision framework was used to formulate the recommendations. RESULTS: The task force committee concluded with recommendations for 25 PICO and 28 narrative questions, regarding ILD in the context of systemic sclerosis, rheumatoid arthritis (RA), idiopathic inflammatory myopathies, Sjögren disease (SjD), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). In four narrative questions, regarding screening and assessment of risk for ILD progression in MCTD, SjD and SLE and one PICO question regarding pirfenidone in CTD-ILD other than RA-ILD, the task force had insufficient evidence to support recommendations. Screening, diagnostic, monitoring and treatment algorithms were developed based on the recommendations and usual clinical practice. CONCLUSIONS: We provide practical guidance by evidence-based recommendations to clinicians for each of the CTDs. In many cases there is low certainty or absence of evidence and we encourage further research to fill these gaps.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Antoniou KM, Distler O, Gheorghiu AM, et al. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG). Ann Rheum Dis. 2025. PMID: 40912974. doi:10.1016/j.ard.2025.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。